drugset / Trial / NCT06708780
Immunotherapy with Autologous Tregs in T1DM
Phase 1
Recruiting
20 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Shanghai Institute of Materia Medica, Chinese Academy of Sciences · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Type 1 diabetes (T1D) is an autoimmune disease characterized by a progressive immune distruction of pancreat beta cells and deterioration of endogenous insulin secretion. Regulatory T cells (Treg) are fuctionally deficient in T1D, leading to the loss of immune tolerance to the islets and the initiation of an autoimmune attack. Previouse studies have revealed the potential theraputic effects of autologous Treg transplantation in T1D. We have modified the preparation protocol for autologous Tregs. The purpose of this study is to assess the safety and effect of autologous Treg therapy in patients with T1D.
Timeline
- Start
- 2023-04-12
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ex vivo Expanded Human Autologous Regulatory T Cells | Cell therapy | — | — |